UpTempo℠ AAV Platform Process
Summary: A scalable, CGMP-ready process for viral vector manufacturing that reduces the current 18-20-month development timeline for drug product in half.
Plasmid Platform Facilitates Transition to Clinic
Summary: Securing the supply of this critical raw material will help biotech and pharma companies throughout the drug development lifecycle of their advanced therapies.
Platform Processes for Streamlined Regulatory Filing and Decreased Time to Market for Gene Therapies
Summary: In this podcast, we will discuss how Catalent is working to simplify the supply chain, develop processes scalable for late-stage and commercial needs, and accelerate timelines for production of clinical materials.
Accelerating Advances in Cell and Gene Therapy Production
Summary: During this webinar, we reviewed progress in several areas of advanced development and their impact on readiness for large scale manufacturing.
Plasmid DNA: Integrated Solutions for Cell and Gene Therapies
Summary: Plasmid DNA is a critical raw material for cell and gene therapies. Discover the importance of having an integrated partner like Catalent Cell & Gene, and how we can keep your development and manufacturing on track and on schedule.
Plasmid DNA Manufacturing
Summary: The Catalent team has broad expertise in developing customized plasmid DNA manufacturing solutions, from plasmid engineering to large-scale GMP plasmid production.